Blogs
NICE balks at Spinraza price, rejects reimbursement in its draft guidance
By Christina Poschen, Consultant Email: [email protected] Biogen’s Spinraza, a treatment for the rare genetic disease spinal muscular atrophy (SMA) is currently making headlines for its